Combination therapy for cancer
AssigneeEli Lilly and Company
InventorEdward Michael Chan
Life of this patent
Estimating the term…
Abstract
The present invention provides preparation of medicaments for use in treating and methods of treating non-small cell lung cancer in a patient comprising: [5-(4-ethyl-piperazin-1-ylmethyl)-pyridin-2-yl]-[5-fluoro-4-(7-fluoro-3-isopropyl-2-methyl-3H-benzoimidazol-5-yl)-pyrimidin-2-yl]-amine, or a pharmaceutically acceptable salt thereof, in combination, as further described herein, with an anti-VEGFR2 antibody, preferably, ramucirumab.
Claims6
A method of treating non-small cell lung cancer in a human patient, comprising administering to a non-small cell lung cancer human patient in need of such treatment 300 or 400 mg daily of a compound of the formula:
- or a pharmaceutically acceptable salt thereof, in combination with 10 mg/kg once every three weeks of ramucirumab.
A method of treating non-small cell lung cancer in a human patient, comprising administering to a non-small cell lung cancer human patient in need of such treatment 300 or 400 mg daily of a compound of the formula:
- or a pharmaceutically acceptable salt thereof, in combination with 10 mg/kg of ramucirumab on the first day of a 21-day cycle.
Dependencies are inferred from the claim text.